PDCD1 and melanoma: However, by mapping the expression profile of the low- and high-risk group with a public dataset of 47 melanoma patients responded to immunotherapies in SubMap modules of GenePattern [60], the low-risk group showed prospective response to anti-PD-1 (programmed cell death protein 1) therapy (Bonferroni-corrected P = 0.008, Fig. 8A).